Logo image of MEDP

MEDPACE HOLDINGS INC (MEDP) Stock Fundamental Analysis

NASDAQ:MEDP - Nasdaq - US58506Q1094 - Common Stock - Currency: USD

323.54  -3.78 (-1.15%)

Fundamental Rating

7

Overall MEDP gets a fundamental rating of 7 out of 10. We evaluated MEDP against 55 industry peers in the Life Sciences Tools & Services industry. MEDP gets an excellent profitability rating and is at the same time showing great financial health properties. MEDP is not overvalued while it is showing excellent growth. This is an interesting combination. This makes MEDP very considerable for growth and quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

In the past year MEDP was profitable.
In the past year MEDP had a positive cash flow from operations.
In the past 5 years MEDP has always been profitable.
In the past 5 years MEDP always reported a positive cash flow from operatings.
MEDP Yearly Net Income VS EBIT VS OCF VS FCFMEDP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

1.2 Ratios

MEDP has a better Return On Assets (19.25%) than 98.18% of its industry peers.
Looking at the Return On Equity, with a value of 48.98%, MEDP belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
The Return On Invested Capital of MEDP (37.95%) is better than 98.18% of its industry peers.
MEDP had an Average Return On Invested Capital over the past 3 years of 38.75%. This is significantly above the industry average of 10.20%.
Industry RankSector Rank
ROA 19.25%
ROE 48.98%
ROIC 37.95%
ROA(3y)18.14%
ROA(5y)15.16%
ROE(3y)54.33%
ROE(5y)40%
ROIC(3y)38.75%
ROIC(5y)29.27%
MEDP Yearly ROA, ROE, ROICMEDP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

1.3 Margins

MEDP's Profit Margin of 19.17% is amongst the best of the industry. MEDP outperforms 94.55% of its industry peers.
MEDP's Profit Margin has improved in the last couple of years.
The Operating Margin of MEDP (21.19%) is better than 89.09% of its industry peers.
In the last couple of years the Operating Margin of MEDP has grown nicely.
With a Gross Margin value of 31.12%, MEDP is not doing good in the industry: 72.73% of the companies in the same industry are doing better.
MEDP's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 21.19%
PM (TTM) 19.17%
GM 31.12%
OM growth 3Y6.82%
OM growth 5Y7.46%
PM growth 3Y6.48%
PM growth 5Y10.5%
GM growth 3Y2.7%
GM growth 5Y1.75%
MEDP Yearly Profit, Operating, Gross MarginsMEDP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30 40

More info and screens

8

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), MEDP is creating value.
The number of shares outstanding for MEDP has been reduced compared to 1 year ago.
The number of shares outstanding for MEDP has been reduced compared to 5 years ago.
There is no outstanding debt for MEDP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MEDP Yearly Shares OutstandingMEDP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
MEDP Yearly Total Debt VS Total AssetsMEDP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

MEDP has an Altman-Z score of 6.36. This indicates that MEDP is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 6.36, MEDP belongs to the best of the industry, outperforming 89.09% of the companies in the same industry.
MEDP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 6.36
ROIC/WACC3.41
WACC11.14%
MEDP Yearly LT Debt VS Equity VS FCFMEDP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 0.93 indicates that MEDP may have some problems paying its short term obligations.
MEDP has a worse Current ratio (0.93) than 87.27% of its industry peers.
MEDP has a Quick Ratio of 0.93. This is a bad value and indicates that MEDP is not financially healthy enough and could expect problems in meeting its short term obligations.
MEDP has a worse Quick ratio (0.93) than 78.18% of its industry peers.
MEDP does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
Industry RankSector Rank
Current Ratio 0.93
Quick Ratio 0.93
MEDP Yearly Current Assets VS Current LiabilitesMEDP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 42.23% over the past year.
Measured over the past years, MEDP shows a very strong growth in Earnings Per Share. The EPS has been growing by 33.22% on average per year.
The Revenue has grown by 11.83% in the past year. This is quite good.
MEDP shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.62% yearly.
EPS 1Y (TTM)42.23%
EPS 3Y37.96%
EPS 5Y33.22%
EPS Q2Q%49.19%
Revenue 1Y (TTM)11.83%
Revenue growth 3Y22.68%
Revenue growth 5Y19.62%
Sales Q2Q%7.66%

3.2 Future

MEDP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.85% yearly.
MEDP is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.22% yearly.
EPS Next Y-0.09%
EPS Next 2Y5.69%
EPS Next 3Y8.87%
EPS Next 5Y10.85%
Revenue Next Year2.79%
Revenue Next 2Y6.27%
Revenue Next 3Y8.17%
Revenue Next 5Y11.22%

3.3 Evolution

Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
MEDP Yearly Revenue VS EstimatesMEDP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B 4B 5B
MEDP Yearly EPS VS EstimatesMEDP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 10 20 30

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 25.62 indicates a quite expensive valuation of MEDP.
Compared to the rest of the industry, the Price/Earnings ratio of MEDP indicates a somewhat cheap valuation: MEDP is cheaper than 78.18% of the companies listed in the same industry.
MEDP is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 29.98, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 25.64, which means the current valuation is very expensive for MEDP.
MEDP's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. MEDP is cheaper than 74.55% of the companies in the same industry.
MEDP's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.66.
Industry RankSector Rank
PE 25.62
Fwd PE 25.64
MEDP Price Earnings VS Forward Price EarningsMEDP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

83.64% of the companies in the same industry are more expensive than MEDP, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, MEDP is valued cheaply inside the industry as 89.09% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 17.23
EV/EBITDA 19.54
MEDP Per share dataMEDP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60

4.3 Compensation for Growth

MEDP has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.77
EPS Next 2Y5.69%
EPS Next 3Y8.87%

More info and screens

0

5. Dividend

5.1 Amount

MEDP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MEDPACE HOLDINGS INC

NASDAQ:MEDP (3/3/2025, 2:39:23 PM)

323.54

-3.78 (-1.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-10 2025-02-10/amc
Earnings (Next)04-21 2025-04-21/amc
Inst Owners84.94%
Inst Owner Change-0.72%
Ins Owners0.5%
Ins Owner Change0.47%
Market Cap9.86B
Analysts75
Price Target355.11 (9.76%)
Short Float %4.48%
Short Ratio4.28
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.91%
Min EPS beat(2)6.19%
Max EPS beat(2)21.62%
EPS beat(4)4
Avg EPS beat(4)15.34%
Min EPS beat(4)6.19%
Max EPS beat(4)27.27%
EPS beat(8)7
Avg EPS beat(8)12.33%
EPS beat(12)11
Avg EPS beat(12)15.99%
EPS beat(16)15
Avg EPS beat(16)14.34%
Revenue beat(2)0
Avg Revenue beat(2)-2.49%
Min Revenue beat(2)-3.35%
Max Revenue beat(2)-1.63%
Revenue beat(4)0
Avg Revenue beat(4)-2.32%
Min Revenue beat(4)-3.35%
Max Revenue beat(4)-1.63%
Revenue beat(8)3
Avg Revenue beat(8)0.03%
Revenue beat(12)6
Avg Revenue beat(12)0.41%
Revenue beat(16)7
Avg Revenue beat(16)-0.09%
PT rev (1m)-0.29%
PT rev (3m)-2%
EPS NQ rev (1m)1.6%
EPS NQ rev (3m)1.77%
EPS NY rev (1m)-1.76%
EPS NY rev (3m)-0.96%
Revenue NQ rev (1m)-1.32%
Revenue NQ rev (3m)-1.71%
Revenue NY rev (1m)-2.73%
Revenue NY rev (3m)-2.94%
Valuation
Industry RankSector Rank
PE 25.62
Fwd PE 25.64
P/S 4.67
P/FCF 17.23
P/OCF 16.19
P/B 11.94
P/tB 76.55
EV/EBITDA 19.54
EPS(TTM)12.63
EY3.9%
EPS(NY)12.62
Fwd EY3.9%
FCF(TTM)18.78
FCFY5.8%
OCF(TTM)19.98
OCFY6.18%
SpS69.22
BVpS27.09
TBVpS4.23
PEG (NY)N/A
PEG (5Y)0.77
Profitability
Industry RankSector Rank
ROA 19.25%
ROE 48.98%
ROCE 44.85%
ROIC 37.95%
ROICexc 115.67%
ROICexgc N/A
OM 21.19%
PM (TTM) 19.17%
GM 31.12%
FCFM 27.13%
ROA(3y)18.14%
ROA(5y)15.16%
ROE(3y)54.33%
ROE(5y)40%
ROIC(3y)38.75%
ROIC(5y)29.27%
ROICexc(3y)71.87%
ROICexc(5y)52.56%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)47.22%
ROCE(5y)35.45%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y64.05%
ROICexc growth 5Y48.31%
OM growth 3Y6.82%
OM growth 5Y7.46%
PM growth 3Y6.48%
PM growth 5Y10.5%
GM growth 3Y2.7%
GM growth 5Y1.75%
F-Score8
Asset Turnover1
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 124.95%
Cap/Sales 1.73%
Interest Coverage 2613.27
Cash Conversion 127.87%
Profit Quality 141.53%
Current Ratio 0.93
Quick Ratio 0.93
Altman-Z 6.36
F-Score8
WACC11.14%
ROIC/WACC3.41
Cap/Depr(3y)142.96%
Cap/Depr(5y)144.54%
Cap/Sales(3y)2.07%
Cap/Sales(5y)2.41%
Profit Quality(3y)141.71%
Profit Quality(5y)142.32%
High Growth Momentum
Growth
EPS 1Y (TTM)42.23%
EPS 3Y37.96%
EPS 5Y33.22%
EPS Q2Q%49.19%
EPS Next Y-0.09%
EPS Next 2Y5.69%
EPS Next 3Y8.87%
EPS Next 5Y10.85%
Revenue 1Y (TTM)11.83%
Revenue growth 3Y22.68%
Revenue growth 5Y19.62%
Sales Q2Q%7.66%
Revenue Next Year2.79%
Revenue Next 2Y6.27%
Revenue Next 3Y8.17%
Revenue Next 5Y11.22%
EBIT growth 1Y32.67%
EBIT growth 3Y31.04%
EBIT growth 5Y28.55%
EBIT Next Year11.4%
EBIT Next 3Y12.68%
EBIT Next 5Y14.09%
FCF growth 1Y44.25%
FCF growth 3Y34.54%
FCF growth 5Y25.47%
OCF growth 1Y40.48%
OCF growth 3Y32.23%
OCF growth 5Y24.7%